Metabolism-Based Molecular Subtyping Endows Effective Ketogenic Therapy in p53-Mutant Colon Cancer

Meng Tang, Hui Xu, Hongyan Huang, Hao Kuang, Chenxi Wang, Qin Qin Li, Xin Zhang, Yizhong Ge, Mengmeng Song, Xi Zhang, Ziwen Wang, Chaobing Ma, Jinlin Kang, Wanfang Zhang, You Wang, Bo Zhang, Xiaowei Zhang, Yongbing Chen, Minghua Cong, Gerry Melino, Xiaobin Wang, Fuxiang Zhou,* Qiang Sun,* and Hanping Shi*

Although targeting cancer metabolism is a promising therapeutic strategy, clinical success depends on accurate molecular and metabolic subtyping. Here, this study reports two metabolism-based molecular subtypes associated with the ketogenic treatment of colon cancer: glycolytic (glycolysis+/ketolysis−) and ketolytic (glycolysis−/ketolysis+), which are manifested by distinct profiles of metabolic enzymes and mitochondrial dysfunction, and by different responses to ketone-containing interventions in vitro and in vivo. Notably, the glycolytic subtype is able to be transformed into the ketolytic subtype in p53-mutated tumors upon glucose limitation, rendering resistance to ketogenic therapy associated with upregulation of ketolytic enzymes, such as OXCT1 by mutant p53. The allosteric activator of mutant p53 effectively blocks the rewired molecular expression and the reprogrammed metabolism, leading to the suppression of tumor growth. The findings highlight the utility of metabolic subtyping to guide ketogenic therapy in colon cancer and identify mutant p53 as a synthetic lethality target for ketogenic treatment.

1. Introduction

Metabolic reprogramming during tumorigenesis is an essential process in cancer cells. Most solid tumors share the common characteristics of uncontrolled cell proliferation, high demand of energy for cellular growth,[1] and increased glucose uptake and dependence on glycolysis.[2] The primary example of metabolic reprogramming was discovered by Otto Warburg: tumor cells can shift from oxidative to fermentative metabolism during the process of oncogenesis.[3] Recently, the extensive reprogramming of glycolytic activity mediated by posttranslational regulation through phosphorylation has been described,[4] for example, tyrosine phosphorylation of enolase (ENO1), pyruvate kinase M (PKM), and phosphoglycerate mutase 1 (PGAM1) and serine

DOI: 10.1002/advs.202201992
phosphorylation of PFKP were significantly increased,[5] leading to enzymatic activation and notable changes in the intracellular level of glycolytic metabolites.[6] These metabolic features have prompted substantial investigations in both preclinical and clinical trials, in which several metabolism-targeted agents not only inhibited tumor growth but also improved therapeutic sensitivity.[7] One of which is the modification of diet, such as ketogenic diet (KD), a high-fat, low-carbohydrate diet with adequate amounts of protein.[8] KD mimics the fasting state by decreasing serum glucose levels while simultaneously elevating the levels of ketone bodies as alternative energy.[9] It has received great attention because it is safe, low cost, and feasible to implement in both experiments and in clinical settings. Unlike other nutrients, such as essential amino acids, systemic reduction of glucose levels can be achieved by KD.[10]

However, KD therapy also faces challenges. Previous studies have indicated that the effectiveness of KD as a potential anticancer intervention depends on the functionality of necessary ketolytic enzymes.[11] Just as cancer varies greatly in genomic alterations during oncogenesis and proliferation, cancer metabolic reprogramming is also highly heterogeneous under glucose stress,[12] part of which is attributed to ketolytic enzyme activities[13] or mitochondrial autophagy.[14] Therefore, defining metabolic subtypes and elucidating underlying metabolic reprogramming are critical to advance precision KD therapy.

In this study, we hypothesize that in colon cancer, on the one hand, the Warburg effect can be harnessed to serve as an anti-tumor target for dietary intervention, i.e., creating chronic low glucose stress by a KD; on the other hand, the effectiveness of KD varies by individual cancer’s metabolic subtyping, i.e., its ability to adapt to such stress. By screening the baseline molecular profiles in existing datasets of colon cancer patients, we identified different energy metabolic subtypes and investigated their responses to KD treatment. Most remarkably, we found that p53

2. Results

2.1. Metabolic Heterogeneity in Colon Cancer

As the key energy suppliers of cancer cells, the metabolism of glucose and ketone bodies is controlled by a set of key molecules (Figure 1A,B); therefore, we set out to explore the characteristics of colon cancer metabolism by analyzing 16 genes associated with glucose and ketone body metabolic pathways through the Gene Expression Profiling Interactive Analysis (GEPIA) network. As a result, The Cancer Genome Atlas (TCGA) transcriptomics and clinical data were retrieved for 275 patients with colon cancer, along with 41 matched noncancer colon samples. Comparison of the gene expression scores revealed in tumor tissues a decrease of the ketolytic enzyme acetyl-CoA acetyltransferase (ACAT1) and a trend of decrease in 3-oxoadipate-CoA-transferase 1 (OXCT1) and d-3-hydroxybutyrate dehydrogenase (BDH1), along with low expression of the oxidative phosphorylation (OXPHOS) factor peroxisome proliferator activated receptor γ coactivator-1α (PGC-1α) (Figure 1A, upper panel). The gene expression levels of OXCT1 and ACAT1 in each colon cancer patient varied greatly, suggesting notable differences in ketolytic metabolism. In contrast, most tumor tissues demonstrated higher expression of glucose transporter 1 (GLUT1) (with significance) together with superior levels of its downstream molecules 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3), pyruvate kinase M (PKM), and lactate dehydrogenase A (LDHA) (trend only) (Figure 1A, lower panel). These results suggested considerable heterogeneity in the metabolism of glucose and ketone bodies in colon cancer.

2.2. Molecular Classification of Metabolic Subtypes

To delineate metabolic heterogeneity and identify molecular subtypes of colon cancer that would be sensitive or resistant to ketogenic diet, we selected 782 colon cancer patients from a transcriptome database and randomly divided them into two cohorts: a test cohort consisting of 521 patients with detailed information for clinical and metabolic signature analysis and a validation cohort consisting of 261 patients. Using univariate Cox regression analysis and the least absolute shrinkage and selection operator (LASSO) of the above identified genes, we identified two glycolytic enzymes (GLUT1 and PFKFB3) (Figure S1A, Supporting Information), which, together with the two ketolytic enzymes (OXCT1 and ACAT1), constitute a molecular signature of colon cancer prognosis in the context of ketogenic diet (Figure S1B, Supporting Information). The prognostic value of the four biomarkers, accounting for clinicopathological factors, was assessed by Kaplan–Meier (KM) curve, univariate Cox regression and multivariate Cox regression analyses. In general, the overexpression of GLUT1 (HR = 1.57, 95% CI: 1.22–2.02, P = 0.001) and PFKFB3 (HR = 1.60, 95% CI: 1.13–2.27, P = 0.009) indicated poor outcomes, whereas OXCT1 (HR = 0.76, 95% CI: 0.58–0.98, P = 0.036) and ACAT1 (HR = 0.77, 95% CI: 0.61–0.99, P = 0.037) indicated favorable overall survival for patients with colon cancer (Figure 1C). Next, by considering the combined biomarkers, we defined two molecular metabolism phenotypes of colon cancer: a glycolysis-proficient phenotype (glycolysis⁺) with either GLUT1 or PFKFB3 overexpression and a ketolysis-deficient (ketolysis⁻) phenotype by null expression of either OXCT1 or ACAT1. The
A

Relative expression

ACAT1

OXCT1

BDH1

PGC1α

GLUT1

PFKFB3

PKM

LDHA

B

Tumor

Non-tumor

Glucose

G1P → G6P → Ribulose-5-P

2,6BP → FEP

Glyceraldehyde 3-P → Glycerol-3-P

3-Phosphoglycerate → Serine

β-HB

AcAc

PEP

AcCoA

Pyruvate

Lactate

Malate

Fumarate

Citrate

Lipoate

ERC

C

D

Glycolysis

Ketolysis

GLUT1

PFKFB3

OXCT1

ACAT1

Overall survival (%)

Time (Months)

Log-Rank

p = 0.001

p = 0.008

p < 0.001

p = 0.036

p = 0.037

K

G-K+ (76)

G-K+ (214)

G-K+ (92)

G-K+ (410)

G-K+ (19)

G-K+ (19)

G-K+ (18)

G-K+ (18)

p = 0.057

p = 0.069

p = 0.018

p = 0.002

HR = 2.96

F

Glycolysis

Ketolysis

GLUT1

PFKFB3

OXCT1

ACAT1

Overall survival (%)

Time (Months)

Log-Rank

p = 0.018

p = 0.002

HR = 3.96

E

Glycolysis++ / Ketolysis++

cancer tissue

Glycolysis++ / Ketolysis++

cancer tissue

Glycolysis− / Ketolysis++

cancer tissue

Glycolysis− / Ketolysis++

cancer tissue

Glycolysis− / Ketolysis−

non-cancerous tissue

DAPI

GLUT1

PFKFB3

OXCT1

ACAT1

F

Glycolysis

Ketolysis

GLUT1

PFKFB3

OXCT1

ACAT1

Overall survival (%)

Time (Months)

Log-Rank

p = 0.018

p = 0.002

HR = 3.96

2201992 (3 of 21) © 2022 The Authors. Advanced Science published by Wiley-VCH GmbH
patients with tumors of either glycolysis+ or ketolysis+ displayed poor prognosis (Figure 1D, upper panel).

Furthermore, by composite phenotypes, we stratified colon cancer into three prognostic subtypes: the glycolysis+/ketolysis− subtype (G+/K−; GLUT1high or PFKFB3high, OXCT1low or ACAT1low) demonstrating the worst survival, while the glycolysis−/ketolysis+ subtype (G−/K+; GLUT1low and PFKFB3low, OXCT1high and ACAT1high) demonstrating the most favorable prognosis, and the hybrid phenotype (G+/K− or G−/K+) that demonstrates intermediate survival (Figure 1D, lower panel).

2.3. Multiplex Staining-Based Validation of Metabolic Subtyping

To further validate the metabolic molecular signature at the translational level, we employed a multiplex immunohistochemical (mIHC) method, which allows concurrent staining of multiple (up to 7) molecules, to illuminate the expression patterns of the four signature enzymes identified above in a colon cancer tissue microarray (Figure 1E and Figure S1C, Supporting Information). The four molecules are expressed in different cells and frequently do not overlap with each other. Importantly, the same prognostic tendencies were confirmed for the individual metabolic molecules (Figure S1D, Supporting Information), for the two metabolic phenotypes (Figure 1F, upper panel), and for the combined metabolic subtypes (mOS in the G−/K+ subtype > 60 months vs mOS in the G+/K− subtype = 27 months, HR = 3.96, 95% CI: 1.60–9.81, p = 0.002) (Figure 1F, lower panel). Taking advantage of the differences in the expression of glycolytic and ketolytic enzymes between colon carcinoma and adjacent tissues, the cancer patients of the G+/K− subtype, for enhanced glycolysis and impaired ketolysis, are the ideal population for ketogenic feeding as compared with those in the SD group (Figure 1C), which was correlated with decreased blood glucose (<4.5 mmol L−1) along with increased ketone bodies (>1.2 mmol L−1) (Figure 2D). Body weight changes between the SD and KD groups were also noticed in the PDX models. Nevertheless, after adjusting the factor of the body weight loss, the tumor-suppression role of KD intervention was still significant between the two groups (tumor volume/weight at the endpoint).

To explore the molecular impacts of the ketogenic diet, samples fed with either SD or KD were collected from the best responsive PDX tumors and subjected to proteomic analysis. The principal component analysis (PCA) clearly separated the KD group from the SD group, with the KD samples distributed in a more heterogeneous pattern (Figure 3A). Analysis of the differentially expressed molecules identified that the KEGG pathways related to arginine and proline metabolism, PPAR signaling, calcium signaling, and GMP-PKG signaling were significantly upregulated upon KD treatment (Figure 3B, C). Gene Ontology (GO) analysis revealed upregulation of molecules involved in the cellular response to fatty acids and lipid oxidation and regulation of transmembrane transporter activity (Figure 3D), consistent with which molecules related to oxidoreductase activity and calcium ion binding (Figure 3E) and those belonging to integral components of the mitochondrial membrane (Figure 3F and Figure S2, Supporting Information) were also upregulated. Conversely, molecules involved in the regulation of cellular and macromolecule biosynthetic processes were downregulated (Figure 3G).

Moreover, the deregulated molecules formed several interactive components related to lipid metabolism in mitochondria (Figure 3H). Importantly, under ketogenic treatment, the glycolysis pathway was suppressed, as evidenced by downregulated GLUT1, HK2, PFKM, and LDHA (Figure 3I), while the mitochondrial OXPHOS pathway was less affected, which may help ensure ketogenic treatment sensitivity.

Figure 1. Metabolic heterogeneity and molecular-based stratification in colon cancer. A) Gene expression scores of metabolic molecules between colon cancer tissues (red) and noncancer tissues (gray) through the GEPIA network (log2FC = 1, which is defined as median (tumor) − median (normal), log scale: log2(TPM+1), *P < 0.01). B) Schematic diagram of glucose and ketone body metabolism. Key molecules are marked with color. C) Kaplan–Meier curve and Cox regression analysis of overall survival (OS) for metabolic molecules of 782 colon cancer patients in the GEO dataset (GSE39582, GSE17536, and GSE17537). D) Kaplan–Meier analysis of overall survival (OS) for glycolytic and ketolytic combined phenotypes at the transcriptional level. (Glycolysis type: GLUT1/PFKFB3, Chi square = 17.33, P < 0.001; ketolysis type: OXCT1/ACAT1, Chi square = 7.10, P = 0.008; glycolysis/ketolysis: Chi square = 20.37, P = 0.001, mOS (G+/K−) = 102.4 months, mOS (G−/K+) > 160.8 months). Statistical analyses were generated using the log-rank test. E) Immunohistochemical staining and multiplexed immunofluorescence (Opal-7) analysis of glycolytic and ketolytic combined phenotypes in colon carcinoma and adjacent tissues. Blue indicates DAPI (nuclear staining), magenta indicates CK (epithelium), red-GLUT1, orange-PBFK3, cyan-OXCT1, and green-ACAT1. F) Kaplan–Meier analysis of overall survival (OS) time for the combined metabolic phenotypes of colon cancer microarray (glycolysis type: GLUT1/PFKFB3, Chi square = 4.18, P = 0.057; ketolysis type: OXCT1/ACAT1, Chi square = 5.26, P = 0.069; glycolysis/ketolysis: Chi square = 11.30, P = 0.018, mOS (G+/K−) = 27 months, mOS (G−/K+) > 60 months). Statistical analyses were generated using the log-rank test.
Figure 2. Ketogenic treatment inhibited tumor growth in ketolysis-deficient PDX models of colon cancer. A) Flowchart of patient-derived xenograft (PDX) models based on metabolic subtyping. B) Multiplexed immunofluorescence staining (Opal-4) of colon cancer tissues from corresponding PDX sections. Blue indicates DAPI (nuclear staining), green indicates GLUT1, red-OXCT1, and magenta-ACAT1. C) Mouse and tumor images of PDX models after more than two weeks of treatment with the standard diet (SD) and ketogenic diet (KD). Weight and tumor volume were recorded from the third day after grouping treatment with SD or KD until the endpoint. D) Levels of serum glucose and ketone bodies detected from the second day after grouped treatment with SD or KD until the endpoint. Data are presented as the mean ± standard deviation (SD). Two-way ANOVA was performed between the SD and KD groups (n = 3 mice/arm). G⁺/K⁻, glycolysis⁺/ketolysis⁻; G⁺/K⁺, glycolysis⁺/ketolysis⁺.
2.5. Metabolic Characterization of the Glycolytic and Ketolytic Subtypes

To further investigate the metabolic properties of colon carcinoma, five colon cancer cell lines available in the lab were examined for the identification of the metabolic subtype. Considering the suitability of metabolic subtypes and easy-to-culture characteristics, three colon cancer cell lines (SW480, HT29, and SW620), commonly used by other investigators,[15] were selected for further study. As the energy phenotype assay showed (Figure 4A), different cells meet discrepant energy demands via mitochondrial respiration or glycolysis. Among them, SW480 cells were identified as energetic cells that are susceptible to changes in the oxygen consumption rate (OCR), an indication of aerobic respiration, and changes in the extracellular acidification rate (ECAR), a readout of the lactic acid produced from aerobic...
glycolysis (Figure 4B,C). Whereas HT29 cells displayed a relative increase in mitochondria-driven oxygen consumption and ATP production under mitochondrial stress, SW620 cells exhibited complete mitochondrial stagnancy. Moreover, with a view to the expression of glycolytic and ketogenic enzymes (Figure 4D), the SW480 cell line could be defined as the hybrid subtype of glycolysis+/ketolysis−, which displayed extremely active glycolysis and oxidative phosphorylation with overexpression of most key enzymes and possessed a ketogenic ability without any deficiencies of BDH1, OXCT1 or ACAT1. HT29 and SW620 cells were classified as the glycolytic subtype of glycolysis+/ketolysis− with a deficiency of either OXCT1 or BDH1.

In line with the glycolysis subtype (G+/K−), supplementing HT29 and SW620 cells with exogenous beta-hydroxybutyrate (β-HB), the most abundant form of ketone bodies, under glucose-limiting conditions could not restore the cellular ATP levels or mitochondrial membrane potential (MMP), which was in contrast to the responses of the hybrid subtype (G+/K+) SW480 cells (Figure 4E–K). To further confirm an essential role of enzyme expression in molecular subtyping and cellular response to metabolites, OXCT1, whose expression was absent in HT29 cells of the glycolysis subtype (G+/K−), was knocked down in SW480 cells (G+/K+). As expected, OXCT1 knockdown strongly decreased the ability of cells to utilize ketone bodies, as assayed by the decline in MMP, reduction in intracellular ATP and higher levels of spare ketone bodies in culture (Figure 4L–Q).

2.6. Metabolic Reprogramming of Ketolysis: Cells Undergoing Low Glucose Stress

Next, the G+/K− SW480 cells and G+/K+ HT29 cells were examined for their growth under conditions reminiscent of ketogenic therapy, i.e., β-HB plus low glucose (LG). As shown in Figure 5A,B, the growth of the two glycolysis+ cell lines was significantly compromised upon glucose deprivation (LG) over 72 h. Moreover, under LG conditions, β-HB could restore the growth of ketolysis-proficient SW480 cells but not ketolysis-deficient HT29 cells within 48 h, which is in line with expectations. Interestingly, it was noted that the growth inhibition of HT29 cells was partially rescued after 72 h by supplementing β-HB (arrow in Figure 5B), suggesting that metabolic reprogramming took place upon LG stress in HT29 cells, which endowed the ability to utilize β-HB as an energy source to facilitate cell growth. In agreement with this idea, confocal microscopy showed that the number of mitochondria in HT29 cells significantly decreased after 48 h-LG culture (Figure 5C,D), which took place with reduced fragmentation and increased mitochondrial tubulation (Figure 5E–F), suggesting the occurrence of mitochondrial fusion upon LG stress. Consistently, the expression of dynamin-related protein 1 (Drp1) and its phosphorylation at Ser-637 (pS637-Drp1) were downregulated, whereas Drp1 with phosphorylation at Ser-616 (pS616-Drp1), which suppresses mitochondrial fission, was upregulated under glucose-limiting conditions (Figure 5F). In addition, the subunits of mitochondrial respiratory chain complex 1, such as NDUF51 and NDUFV2, were apparently induced. To further confirm the metabolic adaptation under glucose-limiting conditions, HT29 cells were subjected to OCR and transmission electron microscopy (TEM) measurements, which indicated proficient mitochondrial oxidative phosphorylation and enhanced mitochondrial function (Figure 5G–K).

2.7. Metabolic Reprogramming by Mutant p53 Mediated the Uprogulation of Ketolytic Molecules

Moreover, LG stress, but not nonglucose (NG) or serum starvation (SS), strongly induced the expression of the major molecules in the ketolysis pathway, including OXCT1, ACAT1, BDH1, and PGC1a as well (Figure 5I), which underlies metabolic reprogramming in HT29 cells (Figure 5B). Since p53 is a key regulator of metabolism that functions primarily at the transcriptional level,[16] we, therefore, set to examine its involvement in this context. Due to its rather low expression in HT29 cells (Figure 4D) and requirement for ketolytic activity in SW480 cells (Figure 4L–Q), OXCT1 was selected for validation as a proof of principle. Remarkably, bioinformatic analysis identified three potential binding sites for p53 in the 5′ upstream regulatory region of the OXCT1 coding gene (Figure 5M), of which the first site was confirmed to be bound by p53 that is mutated in HT29 cells (Figure S3A–D, Supporting Information) upon LG stress by chromatin immunoprecipitation (ChIP)-qPCR assay (Figure 5N). In agreement with the result, the large PDX tumors with mutated p53 in the KD group (p53-mt-KD resistant, red arrows in Figure 2C) tended to upregulate the expression of molecules of the ketolysis pathway upon ketogenic treatment, as compare with the paired small PDX tumors (p53-mt-KD responsive, green arrows in Figure 2C) or the PDX tumors of wild-type p53 (p53-wt, blue
arrows in Figure 2C) as analyzed by proteomic profiling (Figure 5O and Figure S3E, Supporting Information, for genotyping) and confirmed by immunohistochemical staining and Western Blot (Figure S4, Supporting Information). Additionally, analysis of the GEPIA database revealed a significant positive correlation between p53 and OXCT1 specifically in the tumor tissues of colon cancer, but not in paracancerous tissues or normal colon tissues (Figure S3F–I, Supporting Information). Together, these data fit with a model that mutant p53 mediating metabolic reprogramming by upregulating ketogenic molecules could confer resistance to ketogenic therapy. For those KD-sensitive cases with mutant p53, the underlying mechanisms might be associated with the in vivo balance between energy and nutrition, which warrants further investigation.

2.8. P53 Activator Reverses Mitochondrial OXPHOS Adaptation

Next, we examined the effects of interfering with mutant p53 function by COTI2, an allosteric activator, on metabolic subtyping and ketone body metabolism. As shown in Figure 6A, treatment of p53-mutant HT29 cells with 5 × 10−6 m COTI2 notably reversed the enhanced p53 binding to the site 1 of OXCT1 promoter under ketogenic conditions (significant difference between the LG+HB and LG+HB+Co groups), while there was no significant difference between mutant p53 and BDH1 or ACAT1, respectively. Consistently, exogenous COTI2 inhibited the LG-induced overexpression of ketogenic molecules over a period of 48 hours, including OXCT1, ACAT1, BDH1, and PGC1a, particularly KD-activated OXCT1, in both HT29 cells and SW480 cells (Figure 6B and Figure S5A–C, Supporting Information). This is true for cells cultured in media with either a normal dose of glucose (N) or low glucose (LG), which was marginally affected by further addition of exogenous β-HB. These data suggested that both the G+/K− HT29 and G+/K+ SW 480 cells were constitutively metabolism-reprogrammed, and targeted allosterism of mutant p53 could stabilize the subtype as G+/K−, leading to a compromised utility of ketone bodies and a restored responsiveness to ketogenic therapy. Comconitantly, COTI2 treatment also regulated the morphology of mitochondria in a way toward fission (Figure 6C,D and Figure S5D, Supporting Information), as supported by the strikingly downregulated expression of Ps637 DRP1, NDUFV2, and the like, both in HT29 cells and SW480 cells (Figure 6E and Figure S5E,F, Supporting Information). Consistent with this idea, COTI2 treatment suppressed mitochondrial oxidative phosphorylation in a way even stronger than did OXCT1 knockdown (shOXCT1) (Figure 6F–H), which occurred along with reduced intracellular ATP, declined MPP (Figure 6I–M), and impaired production of acetyl-CoA (Figure S5G,H, Supporting Information) in both SW480 and HT29 cells, and the effects could not be rescued by supplementation with exogenous β-HB (Figure 6N,O). Thus, functional inhibition of mutant p53 by COTI2 may serve as a feasible way to rewire metabolism subtypes and restore responsiveness to ketogenic therapy.

2.9. Targeting Metabolic Reprogramming to Improve the Effectiveness of Ketogenic Treatment

To examine whether targeting mutant p53 could improve the antitumor effect of ketogenic treatment, a cohort of PDX (P4-generation of PDX3 in Figure 2C, G+/K−/p53+/− and HT29 (G+/K+/p53+/−) colon cancer xenografts were fed a KD together with COTI2 agent, respectively. While KD alone displayed tumor-suppressive effects over a two- or three-week period compared with SD treatment, a combination of KD and COTI2 further inhibited tumor growth (Figure 7A–C and Figure S6A,B, Supporting Information). This is correlated with a profound decrease in proliferation, as evidenced by significant reductions in the expression of Ki67 and PCNA (Figure S6C, Supporting Information), which was conceivably attributed to the blocked metabolic reprogramming by mutant p53 inactivation, as COTI2 feeding completely suppressed the expression of ketogenic OXCT1 induced by KD (Figure 7D–F and Figure S6D, Supporting Information), as identified above (Figure 5O). Together, these data consistently identified mutant p53 as a synthetic lethality target for ketogenic treatment of colon cancer.

Figure 5. Metabolic reprogramming under glucose-limiting conditions. A,B) Proliferation curves of SW480 and HT29 cells cultured under N, LG, and LG+HB conditions. Cell numbers were detected by the CCK8 test. Data are presented as the mean ± SD. All of the error bars denote the SD of four replications. *P < 0.05 compared between the LG+HB and LG groups, **P < 0.05 compared between the LG and N groups. C) Mitochondrial morphology of SW480 and HT29 cells cultured under normal (N) and low glucose (LG) conditions for 48 h and stained with MitoTracker (green). D,E) Quantification of mitochondrial numbers and morphology of SW480 and HT29 cells cultured under normal and LG conditions for 48 h. Data are presented as the mean ± SD (30 cells per group). *P < 0.05 compared with the N group. F) Western blot analysis of mitochondrial dynamin-related proteins and subunits of respiratory chain complex I in HT29 cells cultured under N, LG, and NG conditions for 48 h. β-actin was used as an internal control. G–I) Measurement of the OCR in HT29 cells cultured under N and LG conditions for 48 h. Data were normalized by cell numbers. SRC, spare respiratory capacity. J) Representative transmission electron microscopy images of mitochondria in HT29 cells cultured under N and LG conditions for 48 h. K) Quantification of mitochondrial numbers of each cell and morphology (length/width) of each mitochondrion of HT29 cells cultured under N and LG conditions for 48 h. Data are presented as the mean ± SD. Error bars denote the SD of 15 replications (15 cells per group or 15 mitochondria per group). L) Western blot analysis of glycolytic and ketogenic enzymes in HT29 cells cultured under normal, low glucose (LG), nonglucose (NG), and serum starvation (SS) conditions for 24 and 48 h. β-actin was used as an internal control. M) Schematic of the p53 binding motif and sequences in the OXCT1 promoter. N) ChIP-qPCR showing enrichment of p53 binding to the OXCT1 promoter in HT29 cells cultured under NG conditions for 48 h compared with the control. Signals were normalized with cell numbers. The fold changes were calculated by normalization to the input. O) Relative protein expression of metabolic molecules associated with ketogenic, OXPHOS, and glycolytic pathways in colon cancer tissue derived from PDX models. Blue indicates tissues with wild-type p53, green indicates KD-responsive tissues with mutant p53, and red indicates KD-resistant tissues with mutant p53 (Rel. expression, which is defined as the value of the ratio between the KD and SD groups, KD/SD). Data are presented as the mean ± SD. All of the error bars denote the SD of triplicates. #, *P < 0.05, ##, **P < 0.01, ###, ***P < 0.001, ****P < 0.0001.
Figure 6. p53 activator reversed metabolic reprogramming under glucose-limiting conditions. A) ChIP-qPCR test of p53 enrichment on the BDH1, OXCT1, or ACAT1 promoter in HT29 cells cultured under normal (N), low glucose (LG), and containing 5 × 10^{-3} m exogenous β-HB low glucose (LG+HB) conditions with 5 × 10^{-6} m COTI2 for 24 h or without 5 × 10^{-6} m COTI2 for 48 h. The fold changes were calculated by normalization to the input. Data are presented as the mean ± SD. Error bars denote the SD of triplicates. *P < 0.05 compared between the COTI2 group and non-COTI2 group, #P < 0.05 compared between the LG, LG+HB group and N group. The green symbol indicates the significance of BDH1, and the red symbol indicates the significance of OXCT1.
3. Discussion

Whereas aberrant metabolism is well known to be pivotal for tumor development and progression, targeting metabolism for cancer therapy turned out to be challenging largely due to high metabolic heterogeneity, which is particularly true for ketogenic therapy. Aiming at this challenge, in this study, we proposed a guideline of metabolism-based molecular subtyping for effective ketogenic therapy of colon cancer (Figure 8). According to this guideline, colon cancers can be divided into either ketogenic (G+/K-) or glycolytic (G-/K+) subtypes based on the expression of OXCT1, ACAT1, GLUT1, and PFKPF3. Meanwhile, tumors were genotyped on the status of p53 by exon sequencing. On one side, glycolytic tumors with wild-type p53 are supposed to be responsive to KD intervention, whereas those with mutant p53 are recommended to be given KD in combination with allosteric activators of mutant p53, such as COTI2. This helps prevent therapy resistance caused by LG-induced metabolic reprogramming via mutant p53 that triggers the expression of multiple metabolic genes, including OXCT1 reported in this study. On the other side, ketogenic tumors are supposed to be resistant to KD intervention; however, those with mutant p53 might be transformed into KD-responsive tumors by allosteric activators of mutant p53, such as COTI2. Notably, the feasibility of this guideline warrants careful validation in clinical trials in the near future.

In this study, in vitro mitochondrial reprogramming was investigated under glucose-limiting and ketogenic culture conditions, but as a patient-specific multifactorial therapy, the promising antitumor function of the ketogenic diet strictly relies on the created unfavorable metabolic environment for cancer cells. Therefore, the efficiency of in vivo ketogenesis and ketone body utilization regulated by hormones, such as insulin and glucagon, as well as the metabolites of tumors, should be confirmed under KD intervention. In addition, owing to the composition of the ketogenic diet, especially the high fat content, a general concern is that KD may cause deterioration of certain metabolites, such as cholesterol and triglycerides, while some studies point toward an improvement of body composition.[18] In this study, body weight changes were observed in mice bearing colon cancer tissues from different patients, and the underlying mechanisms of KD-induced weight loss, which are associated with the energy–nutrition imbalance in tumors, need further investigation.

Previous studies have reported the bioactive effects of ketone bodies that function as signaling molecules and regulate histone modifications through lysine β-hydroxybutyrylation (Kbbh) by β-hydroxybutyrate (β-HB).[19] In addition, histone Kbbh was proven to be enriched in active gene promoters that further upregulated starvation-responsive metabolic pathways.[20] In this study, based on the metabolic phenotypes, the accumulated β-HB showed a function that promotes unrecoverable impairment in mitochondrial membrane potential and cell proliferation, while ketolysis-deficient cancer cells lost the capacity to adapt to using ketone bodies as highly efficient metabolites. However, the underlying mechanisms of the accumulated β-HB leading to tumor suppression through KD still need further investigation. Furthermore, although four signature molecules (OXCT1, ACAT1, GLUT1, and PFKPF3) were identified in this study to stratify the metabolic subgroups in colon cancer, they may not be the optimal set for other types of cancers. Actually, it is known that cancers initiate multiple metabolic compensations as a result of complicated interactions between cancer cells and microenvironments. In line with this idea, the mutational landscape and the gene expression patterns of glycolytic and ketolytic molecules vary across different cancer types and even different intratumor clones.[21] Compelling evidence demonstrates that multiple subtypes define distinct biological and therapeutic vulnerabilities of cancers, providing a de novo clinically applicable molecular taxonomy,[22] which warrants a comprehensive understanding of tumor therapeutic resistance to develop better strategies.[23] Therefore, a cancer type-oriented discovery of different metabolic signature sets is preferred for more precise metabolic subtyping.

It is noted that the identification of mutant p53 as a driver of metabolic reprogramming in this study does not deny the potential involvement of other oncogenic genes. In fact, many other oncogenic mutations and/or activated signaling pathways, such as Kras mutation and c-Myc, are also important regulators of cancer metabolism; thus, exploring their implications in ketogenic therapy may further shed light on novel therapeutic strategies and guidelines.[18] For example, constitutive activation of Kras signaling by point mutations in either G12V or G13D was shown to drive metabolic reprogramming to promote the development and progression of multiple cancers, such as lung carcinoma.[24] This worked out primarily by increasing the glycolytic activity of cancer cells that consume excessive amounts of glucose to sustain cancer growth. It is conceivable that cells with higher
Figure 7. Reversing metabolic reprogramming promotes sensitivity to ketogenic treatment. A, B) Tumor images and volumes of P4-generation PDX models after a three-week treatment with the standard diet (SD), ketogenic diet (KD), 10 mg kg$^{-1}$ COTI2 (COTI2), or KD combined with 10 mg kg$^{-1}$ COTI2.
glycolytic activity, such as those with Kras mutations, are more vulnerable to glucose restriction. Thus, a composite molecular subtyping targeting both glycolysis and ketolysis would help define a group of cancer patients who are highly responsive to ketogenic therapy, for whom a modified recipe of KD with a medium level of carbohydrates, which are more tolerable to patients, may also be functional in suppressing tumor growth. In light of this point, this study actually sets a basis for more accurate molecular subtyping toward precision ketogenic therapy of multiple cancer types.

4. Experimental Section

Cell Line and Culture Conditions: The human colon cancer cell lines SW480, HT29, and SW620 were normally cultured in DMEM (4.5 g L\(^{-1}\) glucose, 4.0 \(\times\) 10\(^{-3}\) m L-glutamine, without pyruvate) supplemented with 10% fetal bovine serum and 1% penicillin–streptomycin, conventionally placed in a 5% CO\(_2\) incubator at 37 °C. These cell lines were assessed for mycoplasma contamination, and the test results were negative. For subsequent experiments, the medium was discarded gently, washed twice with PBS, and then treated under specific conditions in a 5% CO\(_2\) incubator at 37 °C for 24 or 48 h. To establish a cell model of nutrient deficiency or imitate ketogenic conditions, different procedures used in this study were designed as follows:

(a) Low glucose (LG): low glucose medium (1 g L\(^{-1}\) glucose, 4.0 \(\times\) 10\(^{-3}\) m L-glutamine, without pyruvate) containing 10% fetal serum and 1% penicillin–streptomycin.

(b) Nonglucose (NG): glucose-free medium (0 g L\(^{-1}\) glucose, 4.0 \(\times\) 10\(^{-3}\) m L-glutamine, without pyruvate) containing 10% fetal serum and 1% penicillin–streptomycin.

(c) Serum starvation (SS): serum-free DMEM (4.5 g L\(^{-1}\) glucose, 4.0 \(\times\) 10\(^{-3}\) m L-glutamine, without pyruvate) containing 1% penicillin–streptomycin.

(d) Ketogenic condition (LG+HB): low glucose medium (1 g L\(^{-1}\) glucose, 4.0 \(\times\) 10\(^{-3}\) m L-glutamine, without pyruvate) containing 5 \(\times\) 10\(^{-3}\) m exogenous β-HB, 10% fetal serum, and 1% penicillin–streptomycin.

Colon Cancer Tissue Microarray: A total of 180 sections of colon cancer tissue microarray (TMA: HColA180Su11) were purchased from Shanghai Xinchao Biotechnology Company, involving 93 colon cancer patients (87 pairs of cancer and adjacent tissues and 6 single cancer tissues). From November 2009 to May 2010, colon tissues were obtained by surgical resection at Taizhou Hospital, and a five-year follow-up visit was started from the first month after radical operation. All protocols using human specimens were approved by the Human Ethics Committee of Taizhou Hospital and Shanghai Outdo Biotech Company (YB M-0502), and informed consent was obtained from all patients.

Animals: The animal protocols for mouse studies were approved by the Animal Care and Use Committee of Shijitan Hospital of Capital Medical University (syjly-lx-2020-S3). The animals received humane care according to the Guide for the Care and Use of Laboratory Animals published by the National Academy of Science and the National Institutes of Health. Aside from obesity, the animals were in generally good health.

Diet Formulas: Please refer to Table 1.

Multicolor Immunohistochemistry Analysis: For mIHC staining, the instructions for the Opal Multicolor fluorescent IHC kit (PerkinElmer) were followed. Briefly, the TMA or slide was deparaffinized with xylol and ethanol, and antigen retrieval was performed in A6 solution (pH 6.0) by microwave. After the slide was cooled to room temperature, it was washed in TBST and blocked with blocking buffer for 10 min. Then, the tissues were incubated with primary antibody (Proteintech), followed by Opal-HRP and Opal-fluorogen. The above antigen retrieval and antibody incubation processes were repeated for mIHC staining. The Opal-fluorogen

Table 1. Diet formulas.

| Composition | Standard diet formula\(^{a}\) | Ketogenic diet formula\(^{a}\) |
|-------------|-------------------------------|-----------------------------|
| Mass ratio (caloric ratio) | Mass ratio (caloric ratio) |
| Protein | 18% (0.78 kcal g\(^{-1}\)) | 18.2% (0.73 kcal g\(^{-1}\)) |
| Fat | 4% (0.40 kcal g\(^{-1}\)) | 62.8% (5.56 kcal g\(^{-1}\)) |
| Carbohydrate | 52% (2.21 kcal g\(^{-1}\)) | 2.6% (0.11 kcal g\(^{-1}\)) |
| Moisture | <10% | <10% |
| Fiber | <5% | 4.8% |
| Ash content | <8.0% | 5.2% |
| Others | Vitamins mix and minerals mix\(^{d}\) | |
settings of TMA in this study were as follows: Opal-DAPI; Opal 520-GLUT1 (1:2000); Opal 570-OXCT1 (1:500); Opal 620-CK (1:1000); Opal 650-PPFKFB3 (1:3000); Opal 690-ACAT1 (1:1000). TMA slides were scanned using a confocal microscope (Nikon, Japan), and inform software was used to analyze the images. Fluorescent signaling analysis procedure: tissue segmentation, cell recognition and segmentation, scoring cells based on intensity thresholds and marking each positive cell with a colored dot. All stained cells were observed, and the percentage of positive cells was calculated as %x. The view-color settings are as follows: DAPI-blue, GLUT1-red, PFKFB3-orange; CK-magenta; OXCT1-cyan; ACAT1-green.

Measurement of the OCR and Cell Energy Phenotype in Cells: The Seahorse Extracellular Flux (XF24) Analyzer (XF24, Agilent Technologies) was applied to measure the OCR (XF Cell Mito Stress Test kit, Agilent) and cell energy phenotype (XF Cell Energy Phenotype Test Kit, Agilent) of cancer cells according to the manufacturer’s instructions. Briefly, the cells were plated in a Seahorse XF cell culture microplate at 3 x 10^5 cells (SW480) or 5 x 10^5 cells (HT29) per well, with specific treatment for 48 or 24 h before the subsequent test. The sensor cartridge was hydrated in an Agilent Seahorse XF calibrant at 37 °C in a non-CO2 incubator overnight. The second day, the assay medium was prepared by supplementing Seahorse XF DMEM Base Medium according to the requirement of each test. The assay medium was warmed to 37 °C, and the pH was adjusted to 7.4 with 0.1 N NaOH. Cell culture growth medium was removed from the cell culture microplate, and the cells were washed twice with warmed assay medium. Then, 500 μL assay medium was added, and the microplate was placed into a 37 °C incubator without CO2 for 1 h prior to measurement. Meanwhile, the contents of each punch of the test kit were resuspended with prepared assay medium in volumes according to the instructions.[26] Loading template onto the Seahorse XF24 Analyzer and performing the appropriate procedure for analysis. The relative cell numbers of each sample were further detected by the CCK8 test, which was analyzed on a multiwell scanning spectrophotometer at 450 nm (Molecular Devices, USA).

Western Blot: Immunoblotting was performed as previously described.[27] Briefly, cells or tumor tissues were lysed in RIPA buffer, and protein extraction was carried out on ice. The protein concentration was determined by a BCA protein assay kit (Boster Biological Technology). Total protein lysate was mixed with SDS loading buffer, and proteins were separated by electrophoresis on 10% SDS-PAGE. After that, proteins were transferred onto PVDF membranes. After blocking with 5% skim milk in TBST for 2 h, the membranes were washed and incubated sequentially with primary antibody and anti-mouse or anti-rabbit secondary antibody. Immunostaining with the antibody was performed using ECL western blotting reagents, and densitometric analysis of the immunoblot was carried out using Image Lab software (Bio-Rad).

Intracellular ATP Assay: Intracellular ATP levels were determined by using a confocal microscope (Nikon, Japan), and inform software was designed according to NCBI Primer-BLAST for gene amplification and sequencing.

Mitochondrial Membrane Potential Detection: Mitochondrial membrane potential was detected using the Mitochondrial Membrane Potential Detection assay kit (JC-1) (Beyotime Biotechnology). The appropriate cell density (4 x 10^5/well for SW480 cells, 8 x 10^5/well for HT29 and SW620 cells) was applied to the six-well plate, cultured in normal medium overnight, and then left in specific treatment at the 48 or 24 h time-point before the subsequent test. The cells were harvested into 2 mL mixed buffer with DMEM and JC-1 staining working solution (1:1) and incubated for 20 min in a 37 °C cell incubator for testing. After cell incubation, the supernatant was discarded, washed twice with precooled JC-1 staining buffer, and filtered to form a single-cell suspension. Flow cytometry (Beckman Coulter, USA) was applied to detect JC-1 monomer (green fluorescence, FITC) and JC-1 polymer (red fluorescence, PE) in 10 000 random cells. Relative mitochondrial membrane potential levels were calculated by the ratio of cells with red fluorescence and cells with green fluorescence (CytExpert, Beckman Coulter).

Intracellular Acetyl-CoA Assay: Intracellular acetyl-CoA levels were measured by an acetyl-CoA assay kit (Comin, Bio). The cells were seeded in six-well plates at 1 x 10^5 cells (SW480) or 2 x 10^5 cells (HT29) per well, cultured under normal medium overnight, and then left in specific treatment at the 48 or 24 h time-point before the subsequent test. The cells were harvested in 200 μL lysis buffer according to the instructions. Then, 184 μL acetyl-CoA detection solution was added to the wells of a 96-well plate and placed at room temperature for 5 min. Then, 20 μL of sample was added, and chemiluminescence was immediately measured by a multifunctional microplate reader (PerkinElmer). The values were recorded every 60 s, and the relative concentration (y) of intracellular acetyl-CoA was calculated according to the maximum ΔA (ΔA = A - A0, y = 1640-ΔA 0.012). The protein concentration of each sample was detected by the BCA protein assay kit.

Proliferation Assay: Cell proliferation was determined over a 5-d period by Cell Counting Kit-8 (CCK-8) as described.[28] The cells were seeded in 96-well plates at 2 x 10^3 cells (SW480) or 4 x 10^3 cells (SW620 and HT29) per well, cultured under normal medium overnight, and then left in specific treatment, such as low-glucose (LG), containing exogenous β-HB (LG+βHB), and containing p53 activator conditions (LG+P53), with four repeats. At each detection point, Cell Counting Kit-8 working solution (100 μL/well) was added, and the cells were subsequently incubated for 1 h at 37 °C. Then, the plates were read on a multiwell scanning spectrophotometer at 450 nm (Molecular Devices, USA).

Genomic DNA Extraction and Sequencing: The study sampled the tumor tissue of patient-derived xenograft (PDx) models (50 mg) and cancer cells (1 x 10^5) for DNA extraction. Total genomic DNA was isolated and purified according to the manufacturer’s protocol using a TIANGEN TIANamp Genomic DNA Kit. The DNA sample that processed a minimum concentration of 0.1 μg μL^-1 passed quality control with 1.8 < A 260/280 < 2.0 under a NanoDrop (Thermo Fisher). KRAS and p53 primers were designed according to NCBI Primer-BLAST for gene amplification and sequencing.

Immunofluorescence and Confocal Microscopy: To determine the subcellular distribution of mitochondria and measure the changes in mitochondrial morphology, HT29 and SW480 cells were stained with a 200 x 10^-4 M Mitotracker Green FM assay kit (Thermo Fisher) for 30 min at 37 °C according to the manufacturer’s instructions. After washing with PBS twice, the cells were visualized under a confocal laser scanning microscope (Nikon, Japan) with the 488-nm line. The laser power was at 100 mW. The 488-nm line was used for the excitation of the dye. The images were visualized on an image analysis system (Nikon, Japan).

Transmission Electron Microscopy: HT29 cells were harvested in 1 mm^3 and fixed in 2.5% glutaraldehyde at room temperature. Next, samples were dehydrated in ethanol (with 3% uranyl acetate) and embedded in a mixture of epoxy resin and propylene oxide for 24 h. After the 70-nm-thick sample sections were stained with lead citrate, the mitochondrial morphology was detected under a transmission electron microscope (120 kV, TEM, FEI).

Lentiviral Vector Construction and Infection: According to the gene information (OXCT1,3-oxoacid CoA-transf erase, human; Gene ID: 5019) and mRNA reference sequence (NM_000436.3) in the NCBI database, OXCT1 lentiviral shRNA constructs (with pLent-U6-GFP-Puro lentiviral vector) and the nonfluorescent pLent-U6-Puro lentiviral vector) were established (jinkairui, Wuhan). As described[29] the lentiviral vectors were co-transfected with helper plasmids into 293T cells. The viral supernatant was collected 48 h after transfection and used to infect colon cancer cells (SW480). The fluorescence intensity was observed under a fluorescence microscope, and 6 μg mL^-1 puromycin was added to the cells for 72 h. After the interference efficiency was verified by western blot, cell resistance was persistently maintained with a low concentration of puromycin (2 μg mL^-1).

ChIP and qPCR: ChIP assays were performed with a ChIP kit (Beyotime Biotechnology), and then the TIANamp Genomic DNA kit was used for DNA purification. Briefly, the cells were seeded in 10 cm culture plates
at 5 x 10^5 cells (HT29), cultured in normal medium overnight, and then left in specific treatment at the 48 or 24 h time-point before the subsequent test. The cells were harvested after fixation with formaldehyde and then quantified into 1 x 10^5 cells per pipe for ChIP assays. qPCR analysis was performed to detect DNA fragments immunoprecipitated with anti-p53 antibody (1:200, Proteintech, 10442–1-AP).

**Cell-Derived Xenograft Assays:** Colon cancer cells (HT29, p53<sup>++/−</sup> [C/−]) were routinely cultured to the expected number. Cells were harvested when grown to 80% confluence and resuspended in a suitable medium of fresh medium to a density of 2.5 x 10^7 cells/mL<sup>−1</sup>, added to a 1/5 volume of Matrigel and placed on ice for the next step. Alcohol (75%) was used to wipe the injection site of the nude mice, and 200 μL of the cell suspension was subcutaneously injected into the right side of each BALB/C-nu nude mouse with a 1 mL syringe. Tumor formation was observed, and tumor volume was calculated by the formula (0.52 x length x width x thickness, cm<sup>3</sup>). The nude mice were randomly divided into four groups when the average tumor volume reached ≈0.1 cm<sup>3</sup> (arm > 4). a) SD: normal diet, intraperitoneal injection of the same amount of normal saline; b) P53 agonist (COTI2) group: normal diet, COTI2 was administered continuously for 5 d week<sup>−1</sup>, and intraperitoneal injection was 10 mg kg<sup>−1</sup> only; COTI2 was diluted to 0.3665 mg mL<sup>−1</sup> with normal saline, and the injection volume was calculated by volume. The injection volume of each nude mouse was less than 1 mL; c) KD: ketogenic diet, no calorie restriction, intraperitoneal injection of the same amount of normal saline; d) Group of ketogenic diet combined with P53 agonist (KD+COTI2): ketogenic diet, no calorie restriction. COTI2 was injected intraperitoneally, and the amount was calculated as above. After two weeks of continuous observation, when the tumor volume reached >1.5 cm<sup>3</sup> or the growth activity of nude mice was significantly restricted, the mice were sacrificed by sodium pentobarbital anesthesia, and the subcutaneous tumor was quickly peeled off. After rinsing with physiological saline, half of the tissue was cut and placed in liquid nitrogen, and the rest of the tissue was fixed in 4% paraformaldehyde solution and later embedded in paraffin wax to form paraffin sections.

**Immunohistochemistry:** The paraffin sections were deparaffinized with xylol, ethanol, and demineralized water. Antigens were then retrieved by boiling in 1 x 10<sup>−3</sup> M EDTA (pH 8.0) for 15–20 min. After the sections had been washed in demineralized water and phosphate buffered saline (PBS), the primary antibody was added and incubated for 45 min at 37 °C. After washing with PBS, the sections were incubated with EnVision Mouse or rabbit conjugate for 15 min at 37 °C. The color reaction was completed with the DAB-positive substrate. Sections were counterstained with hematoxylin. Parallel sections were incubated with irrelevant, isotype, and concentration-matched monoclonal antibodies as negative controls. The absence of specific signals to technical failures was further confirmed by including appropriate positive control tissues in each staining run. Nuclear molecular expression was counted with nuclear staining according to the number of positive cells. Cytoplasmic and membranal molecular expression was analyzed according to the integrated optical density (IOD).

**Patient-Derived Xenograft Assays:** Fresh colon cancer samples obtained from patients were immediately subcutaneously inoculated into NSG mice<sup>40</sup> to generate PDX models. After the successfully established PDX (P1) reached 1.0 cm<sup>3</sup> (0.52 x length x width x thickness, cm<sup>3</sup>), the tissues were cut to the second generation (P2), and each mouse was inoculated with tissues of ≈20 mg (2 mm<sup>3</sup>). Eventually, the mouse bearing P3 grafts were randomized into SD and KD groups for further treatment. For further KD and COTI2 investigations, mice bearing P4 grafts of PDX3 were prepared as above, and NSG mice were randomly divided into four groups when the average tumor volume reached ≈0.01 cm<sup>3</sup> (arm > 4). a) SD group: normal diet, intraperitoneal injection of the same amount of normal saline; b) COTI2 group: normal diet, COTI2 was administered continuously for 5 d week<sup>−1</sup>, and intraperitoneal injection was 10 mg kg<sup>−1</sup>; c) KD group: ketogenic diet, no calorie restriction, intraperitoneal injection of the same amount of normal saline; d) KD+COTI2 group: ketogenic diet, no calorie restriction. COTI2 was injected intraperitoneally, and the amount was calculated as above. Weight, serum glucose (YAPEI, China), and serum ketone bodies (YAPEI, China) were measured, and tumor volumes were calculated as previously described. After more than three weeks of continuous observation, when the tumor volume reached ≈1.5 cm<sup>3</sup> or the growth activity of nude mice was significantly restricted, the mice were sacrificed by sodium pentobarbital anesthesia, and the subcutaneous tumor was quickly peeled off. After rinsing with physiological saline, half of the tissue was cut and placed in liquid nitrogen for further analysis, and the rest of the tissue was fixed in 4% paraformaldehyde solution and later embedded in paraffin wax for the paraffin sections.

**4D Label-Free LC-MS/MS Proteomics:** Tumor tissues were obtained from PDX mice as described above (SD and KD groups, n = 3). The samples were grinded with liquid nitrogen into cell powder and dissolved in lysis buffer (8 μL/mL 1% protease inhibitor cocktail), which was followed by sonication three times on ice using a high-intensity ultrasonic processor (Scientz). The supernatant was collected after centrifugation at 12,000 g at 4 °C for 10 min, and the protein concentration was determined with a BCA kit. For digestion, the protein solution was reduced with 5 x 10<sup>−3</sup> M dithiothreitol for 30 min at 56 °C and alkylated with 11 x 10<sup>−3</sup> M iodoacetamide for 15 min at room temperature in darkness. The protein sample was then diluted by adding 100 x 10<sup>−3</sup> M TEAB to a urea concentration less than 2 M. Finally, trypsin was added at a 1:5 trypsin-to-protein mass ratio for the first digestion overnight and a 1:100 trypsin-to-protein mass ratio for a second 4 h digestion. Finally, the peptides were desalted by a C18 SPE column. The tryptic peptides were dissolved in solvent A (0.1% formic acid in water) and directly loaded onto a nanoflow reversed-phase high-performance liquid chromatography (RP-HPLC) analytical column (25 cm length, 75 μm internal diameter).<sup>31</sup> Peptides were eluted at a constant flow rate of 300 nL min<sup>−1</sup> using a gradient of solvent B (0.1% formic acid in acetonitrile), which ramped to 4%-6%-25%-32%-80% B at 2-84-87-90 min on a nanoElute high-performance liquid chromatography (UHPLC) system (Buerk Daltonics). The peptides were subjected to capillary source followed by timsTOF Pro mass spectrometry (Buerk Daltonics) with an electrospray voltage of 1.60 kV. Precursors and fragments were analyzed at the TOF detector, with an MS/MS scan range from 100 to 1700 m/z. The timsTOF Pro was operated in parallel accumulation serial fragmentation (PASEF) mode. Precursors with charge states 0–5 were selected for fragmentation, and 10 PASEF-MS/MS scans were acquired per cycle. The dynamic exclusion was set to 30 s.

**LC-MS/MS Data Processing:** The MS data were processed using Proteome Discoverer (v2.4.1.15) and searched in the UniProt human database (Homo_sapiens_9606_SP_20201214.fasta) while concatenating with the reverse decoy database. Trypsin (Full) was set as the cleavage enzyme, allowing up to two missing cleavages. The mass tolerance for precursor ions was adjusted to 10 ppm, and for fragment ions, it was 0.02 Da. Carbamidomethyl on Cys was set as a fixed modification, while oxidation on Met and acetylation on the protein N-terminus were specified as variable modifications. Peptide and protein false discovery rates (FDRs) were adjusted to <1%. **Analysis of Mitochondrial Morphology:** The length of mitochondria imaged by confocal microscopy was measured using Image-Pro Plus software. Thirty cells were randomly selected from the fields of view, and the length and width of each mitochondrion were measured. According to the percentage of mitochondrial morphology with a length/width ratio greater than 5, cells could be classified into three types: fragmented type (<10%), intermediate type (10%–30%), and tubulated type (>30%). The quantification of mitochondria photographed by TEM was measured using NIS-Elements AR 4.5 software and measured with a length/width.

**Proteomics Analysis of Annotation and Functional Enrichment:** The GO annotation proteome was derived from the UniProt-GOA database (http://www.ebi.ac.uk/GOA/) and InterProScan software (http://www.ebi.ac.uk/interpro/), which was based on the protein sequence alignment method. Proteins were classified by Gene Ontology annotation based on three categories: biological process, cellular component, and molecular function. Functional descriptions of the identified protein domains were annotated by InterProScan software based on the InterPro domain database. Subcellular localization, such as the cytoplasm, nucleus, mitochondria, Golgi apparatus, and endoplasmic reticulum (ER), was predicted by WoLF PSORT software (https://wolfsort.hgc.jp/). The Kyoto Encyclopedia of Genes and Genomes (KEGG) database (https://www.kegg.jp/) was further used to annotate protein pathways.
Table 2. Reagent or resource.

| Reagents or resource | Source | Cat no. |
|----------------------|--------|--------|
| **Antibodies**       |        |        |
| Anti-β-actin, dil:1/5000 | ProteinTech | 66009-1-lg |
| Anti-ACAT1, dil:1/1000 | ABclonal | A13273 |
| Anti-BDH1, dil:1/2000 | ProteinTech | 15417-1-AP |
| Anti-GLUT1, dil:1/1000 | ABclonal | A11170 |
| Anti-LDHA, dil:1/5000 | ProteinTech | 19987-1-AP |
| Anti-NDUF51, dil:1/1000 | ProteinTech | 12444-1-AP |
| Anti-NDUFV1, dil:1/1000 | ProteinTech | 11238-1-AP |
| Anti-NDUFV2, dil:1/1000 | ProteinTech | 15301-1-AP |
| Anti-OXCT1, dil:1/1000 | ProteinTech | 12175-1-AP |
| Anti-PS3, dil:1/1000 | ProteinTech | 10442-1-AP |
| Anti-PFKFB3, dil:1/2000 | ProteinTech | 13763-1-AP |
| Anti-PGC1α, dil:1/1000 | ProteinTech | 22378-1-AP |
| Anti-DRP1, dil:1/1000 | ABclonal | A17069 |
| Anti-phospho-DRP1(S616), dil:1/1000 | ABclonal | AP0849 |
| Anti-phospho-DRP1(S637), dil:1/1000 | ABclonal | AP0812 |
| Anti-Ki67, dil:1/50 | Servicebio | GB11030 |
| Anti-PCNA, dil:1/50 | Servicebio | GB11010 |
| Goat anti-mouse IgG-HRP, dil:1/10000 | Jackson | 115-005-003 |
| Goat anti-rabbit IgG-HRP, dil:1/10000 | Jackson | 111-005-003 |
| **Chemicals, peptides, and recombinant proteins** |        |        |
| Dulbecco’s modified Eagle’s medium (DMEM) | HyClone | SH30243.01 |
| Low-glucose Dulbecco’s modified Eagle’s medium (LG-DMEM) | GENOM | GNM1672 |
| Nonglucose Dulbecco’s modified Eagle’s medium (NG-DMEM) | Gibco | 11966025 |
| Fetal bovine serum (FBS) | HyClone | SH30084.03 |
| Puromycin | Gibco | A1113803 |
| Trypsin | Boster Biol Tech | AR1007 |
| 1% penicillin/streptomycin | Boster Biol Tech | AR1203 |
| DMSO | Sigma | D2650 |
| d-glucose | Sigma | D8270 |
| ECL | Pierce | 23891 |
| l-glutamine | Sigma | G3126 |
| Sodium pyruvate solution | Sigma | S8636 |
| TRIzol | Invitrogen | T9424 |
| RIPA | Boster Biol Tech | AR0102 |
| PMSF | Boster Biol Tech | AR1192 |
| SDS-PAGE protein loading buffer | Boster Biol Tech | AR1112 |
| XF DMEM base medium, pH 7.4, 500 mL | Agilent technologies | 103575-100 |
| Antifluorescent quench sealant | Southernbiotech | 33252 |
| Phosphate buffer | Boster Biol Tech | AR1201 |
| Skimmed milk powder | Becton, Dickinson | 12424 |
| DAPI dye | Beyotime Biotechnology | C1005 |
| Paraffin | Sinopharm | 3112 |
| Anhydrous ethanol | Sinopharm | 3214 |
| 2.5% glutaraldehyde | Solarbio | CP1126 |
| Xylene | Sinopharm | 3452 |
| **Critical commercial assays** |        |        |
| Opal-7 multicolor fluorescent IHC kit | PerkinElmer | NEV20000 |
| BCA Protein assay kit | Boster Biol Tech | AR0197 |
| CCK-8 assay kit | Beyotime Biotechnology | C0037 |

(Continued)
### Table 2. (Continued).

| Reagents or resource | Source                          | Cat no.    |
|----------------------|--------------------------------|------------|
| qPCR assay kit       | Vazyme Biotech                  | R122-01    |
| XF Cell Mito Stress Test kit | Agilent technologies         | 103015-100 |
| XF Cell Energy Phenotype Test Kit | Agilent technologies          | 103325-100 |
| ATP Detection assay kit | Biotime Biotechnology       | S0026      |
| XF Cell Culture Microplates | Agilent technologies | Lot: 33818 |
| XF Extracellular Flux Assay Kit | Agilent technologies   | Lot: B29018 |
| Mitochondrial membrane potential assay kit (JC-1) | Beyotime Biotechnology | C2006       |
| Acetyl-CoA Assay Kit   | Comin Biotech                   | ACA-1-Y     |
| TIANamp Genomic DNA Kit | TIANGEN BIOTECH, BEIJING   | DF304       |
| ChIP Assay Kit         | Beyotime Biotechnology         | P2078       |
| MitoTracker Green FM   | Thermo Fisher                   | M7514       |
| Others                |                                 |            |
| Mouse normal diet      | BEIJING HFK BIOSCIENCE          | 1022       |
| Mouse ketogenic diet    | Jieliang Biotech                | 1025       |
| PVDF membrane          | Millipore                       | IPVH00010  |

### Experimental models: organisms/strains

| BALB/C- nu mice            | Vital River                      | N/A        |
| NSG (NPI, NOD-Prkdc<sup>tm1.L2rg<sup>mel(DMO) mice | IDMO Co.Ltd, Beijing | N/A |

### Deposited Data

| Publicly available transcriptomic datasets from colon cancer patients | GEO database |
|--------------------------------------------------------------|--------------|
| Publicly available transcriptomic datasets from colon cancer tissue | TCGA database |

### Experimental models: cell lines

| Human:HT29 | Procell Life Sci Tech | N/A |
| Human:SW480 | Procell Life Sci Tech | N/A |
| Human:SW620 | Procell Life Sci Tech | N/A |

### Software and algorithms

| Graphpad Prism 8 | GraphPad | https://www.graphpad.com/scientific-software/prism/ |
| SPSS statistics 19.0 | IBM Corporation | https://www.ibm.com/analytics/spss-statistics-software/ |
| CytExpert | Beckman Coulter | https://www.beckman-coulter.cn/ |
| Image Lab | Bio-Rad | https://www.bio-rad.com/ |

### Oligonucleotides

| Oligonucleotides | Source                          | Cat no.    |
|------------------|--------------------------------|------------|
| shRNA1 targeting sequence: OXCT1 | Gene Create | N/A         |
| GCAACTGCCAGCTCAGAAATCTCGAGATTTGCCTCTGATTTT                | Gene Create | N/A         |
| shRNA2 targeting sequence: OXCT1 | Gene Create | N/A         |
| GCCCTGTACAGGGCATGTGGTTTCTCGAGAAACACATCCCGTTTGACCAGGTTTTT | Gene Create | N/A         |
| shRNA3 targeting sequence: OXCT1 | Gene Create | N/A |
| GACCGAGAGGAAAAACGTATTCTGGAAGAAATCGTCTCTCCTGCTCTGCTCTTTTTT | Taihei Biotech | N/A         |
| p53 primer-ex2 (439 bp) | Taihei Biotech | N/A         |
| 2F: TCAGACACTGCCATGCCTGTGTTG; 2R: ATGGAATTTTGCGTCCGAC | Taihei Biotech | N/A         |
| p53 primer-ex3-4 (536 bp) | Taihei Biotech | N/A         |
| 3F: ACTTTCGCTCTGCTCTCTCAC; 4R: AGCCAAAGGTCGACACAGAATC | Taihei Biotech | N/A         |
| p53 primer-exs-6 (590 bp) | Taihei Biotech | N/A         |
| 5F: AGGAGGTGCTTACCAAGTTTGG; 6R: AGGGAGGTCAAATAACACCGCAG | Taihei Biotech | N/A |
| p53 primer-ex7 (304 bp) | Taihei Biotech | N/A         |
| 7F: AGGGAGGTGCTTACCAAGTTTGG; 7R: AGGGAGGTCAAATAACACCGCAG | Taihei Biotech | N/A         |
| p53 primer-ex8-9 (491 bp) | Taihei Biotech | N/A         |
| 8F: AGGAGGTGCTTACCAAGTTTGG; 9R: AGGGAGGTCAAATAACACCGCAG | Taihei Biotech | N/A         |
| p53 primer-ex10 (315 bp) | Taihei Biotech | N/A         |
| 10F: GCAATCTGCCCTTCTGACCAGTC; 10R: AGCTGCCCTTTCACATGAG | Taihei Biotech | N/A |

(Continued)
Table 2. (Continued).

| Oligonucleotides                | Source    | Cat no. |
|---------------------------------|-----------|---------|
| F: gcactgaggggagttgcttg; R: aagaacgggctaatgaaggcac | Taihe Biotech | N/A     |
| F: gGTTTCTGACAGACTATTAGgg; R: gGGTCTGTTTTTCACCTTTGCCct | Tsingke Biotech | N/A     |
| F: CAGACTTTAAAGAATACCATGAAaggcc; R: ggaaAGCACCAGGGCAAGCTCAATAGCA | Tsingke Biotech | N/A     |
| F: AAAAAAGAAACAACTTGGCCGGGAGAAtcc; R: AAGCTCTCTCAAGCCCCTCAggg | Tsingke Biotech | N/A     |
| F: tctggacgacatcaatttggag; R: aacccctcagactgcaagt | Tsingke Biotech | N/A     |
| F: gaacctggaggaggtggcttg; R: aaggaacgctgaatgagaacac | Tsingke Biotech | N/A     |

The transcriptome database containing prognostic information included in this study was from GEO (Gene Expression Omnibus, the Natural Science Foundation of China (131970685 to Q.S.; 81773238 to F.-X.Z.; 32100608 to C.-X.W.; 82029198 to X.Z.), the Key Science & Technology Project of Beijing Educational Committee and the Beijing Municipal Natural Science Foundation (KZ20211003029), Beijing Municipal Administration of Hospitals Incubating Program (PX2021033), the Science and Technology Fund of Zhongnan Hospital, Wuhan University (cxpy2017053 to F.-X.Z.), and the Youth Fund of Beijing Shijitan Hospital, CMU (2019-q02 to T.M.). The authors appreciate the constructive advice from Prof. Jingxuan Kang. The authors also thank PTM Biolabs, Inc. and Beijing IDMO Co. Ltd. for technical assistance. In particular, the authors are very grateful for the in-depth comments and efforts from the reviewers.

Conflict of Interest

The authors declare no conflict of interest.

Author Contributions

M.T., H.X., H.H., and H.K. contributed equally to this work. M.T. and H.X. designed and performed the experiments, analyzed the data, and wrote the manuscript. X.-W.Z., Q.-Q.L., Y.-B.C., and J.-L.K. assisted with the animal experiments. M.T., B.Z., Y.-Z.G., and W.-F.Z. analyzed transcriptomic and sequencing data. M.-M.S. and C.-X.W. assisted with the molecular experiments. H.K., H.-Y.H., Y.W., C.-B.M., X.-B.W., M.-H.C., X.Z., G.M., and H.-P.S. provided constructive suggestions for the project design and edited the manuscript. F.-X.Z. and Q.S. designed the project, prepared the figures, wrote the manuscript, shaped the concept, and supervised the revision.

Materials Availability

This study did not generate new unique reagents.

Data and Code Availability

The comparison of transcriptome data between colon cancer and non-cancer samples was formatted from the GEPIA platform (http://geopia.cancer-pku.cn/), which is based on TCGA database (The Cancer Genome Atlas, https://cancer.gov), including mRNA expression information of 275 colon cancer tissues and 41 colon nontumor tissues.

The transcriptome database containing prognostic information included in this study was from GEO (Gene Expression Omnibus,
The data that support the findings of this study are available from the corresponding author upon reasonable request.

Keywords
colon cancer, ketogenic therapy, metabolic subtype, OXCT1, p53

Received: April 5, 2022
Revised: July 25, 2022
Published online: August 28, 2022

[1] M. Sepulveda-Villegas, R. Rojo, D. Carza-Hernandez, M. de la Rosa-Garza, V. Treviño, Biochim. Biophys. Acta - Mol. Basis Dis. 2020, 1866, 165846.
[2] N. Hay, Nat. Rev. Cancer 2016, 16, 635.
[3] W. Otto, Science 1956, 123, 309.
[4] a) P. Bu, K-Y. Chen, K. Xiang, C. Johnson, S. B. Crown, N. Rakhilin, Y. Ai, L. Wang, R. Xi, I. Astapova, Y. Han, J. Li, B. B. Barth, M. Lu, Z. Gao, R. Mines, L. Zhang, M. Herman, D. Hsu, G.-F. Zhang, X. Shen, Cell Metab. 2018, 27, 1249; b) J. Goodwin, M. L. Neugent, S. Y. Lee, J. H. Choe, H. Choi, D. M. R. Jenkins, R. J. Ruttenborg, M. W. Robinson, J. Y. Jeong, M. Wake, H. Abe, N. Takeda, H. Endo, M. Inoue, Z. Xuan, H. Yoo, M. Chen, J.-M. Ahn, J. D. Minna, K. L. Helke, P. K. Singh, D. B. Shackelford, J. W. Kim, Nat. Commun. 2017, 8, 15503.
[5] S. Dasgupta, K. Rajapakse, B. Zhu, B. C. Nikolai, P. Yi, N. Putluri, J. M. Choi, S. Y. Jung, C. Coarfa, T. F. Westbrook, X. H. Zhang, C. E. Foulds, S. Y. Tsai, M. J. Tsai, B. W. O’Malley, Nature 2018, 556, 249.
[6] G. Bidkhori, R. Benfeitas, M. Klevstig, C. Zhang, J. Nielsen, M. Uhlen, J. Boren, A. Mardinoglu, Proc. Natl. Acad. Sci. USA 2018, 115, E11874.
[7] a) A. Daemen, D. Peterson, N. Sahu, R. McCord, X. Du, B. Liu, K. Kowanez, R. Hong, J. Moffat, M. Gao, A. Boudreau, R. Mroue, L. Conson, T. Obrien, J. Qing, D. Sampath, M. Merchant, R. Yauch, G. Manning, J. Settlement, G. Hatzivassiliou, M. Evangelista, Proc. Natl. Acad. Sci. USA 2015, 112, E4410; b) T. Jin, C. Wang, Y. Tian, C. Dai, Y. Zhu, F. Xu, Cancer Lett. 2020, 470, 197.
[8] A. M. Zavitsanou, T. Papagiannakopoulos, Trends Cell Biol. 2021, 31, 616.
[9] a) P. Puchalska, P. A. Crawford, Cell Metab. 2017, 25, 262; b) F. A. Vallejo, S. S. Shah, N. de Cordoba, W. M. Waiters, J. Prince, Z. Khatib, R. J. Komotor, S. Vanni, R. M. Graham, J. Neurooncol. 2020, 147, 317; c) M. R. Amini, A. Aminianfar, N. Naghshi, B. Larijani, A. Esmaeilzadeh, Crit. Rev. Food Sci. Nutr. 2021, 1, 3644.
[10] N. Kanarek, B. Petrova, D. M. Sabatinii, Nature 2020, 579, 507.
[11] a) H. T. Chang, L. K. Olson, K. A. Schwartz, Nutr. Metab. 2013, 10, 47; b) J. Zhang, P. P. Jia, Q. L. Liu, M. H. Cong, Y. Gao, H. P. Shi, W. N. Yu, M. Y. Miao, J. Lipid Res. 2018, 59, 625.
[27] Z. Zhang, Y. Zheng, Z. Niu, B. Zhang, C. Wang, X. Yao, H. Peng, D. N. Franca, Y. Wang, Y. Zhu, Y. Su, M. Tang, X. Jiang, H. Ren, M. He, Y. Wang, L. Gao, P. Zhao, H. Shi, Z. Chen, X. Wang, M. Piacentini, X. Bian, G. Melino, L. Liu, H. Huang, Q. Sun, Cell Death Differ. 2021, 28, 2765.

[28] a) M. Wang, Z. Niu, H. Qin, B. Ruan, Y. Zheng, X. Ning, S. Gu, L. Gao, Z. Chen, X. Wang, H. Huang, L. Ma, Q. Sun, Cell Rep. 2020, 32, 108071; b) C. Wang, A. Chen, B. Ruan, Z. Niu, Y. Su, H. Qin, Y. Zheng, B. Zhang, L. Gao, Z. Chen, H. Huang, X. Wang, Q. Sun, Front. Cell Dev. Biol. 2020, 8, 329.

[29] Z. Niu, Z. Zhang, X. Gao, P. Du, J. Lu, B. Yan, C. Wang, Y. Zheng, H. Huang, Q. Sun, Signal Transduction Targeted Ther. 2021, 6, 284.

[30] S. Guo, S. Gao, R. Liu, J. Shen, X. Shi, S. Bai, H. Wang, K. Zheng, Z. Shao, C. Liang, S. Peng, G. Jin, FASEB J. 2019, 33, 873.

[31] Y. Jami-Alahmadi, V. Pandey, A. K. Mayank, J. A. Wohlschlegel, J. Vis. Exp. 2021.